Consolidated Statements of Operations and Comprehensive Income/ (Loss) (USD $)	12 Months Ended		211 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Revenues:
Net sales			$ 174,830
Licensing revenue			1,300,000
Grant revenue			618,692
Total net revenue			2,093,522
Cost of goods sold			51,094
Gross margin			2,042,428
Operating expenses:
Research and development	12,902,263	8,088,152	98,959,719
Selling, general and administrative	8,517,781	7,519,405	76,184,493
Transaction-related expenses	79,640	(69,602)	751,292
Depreciation and amortization	39,517	90,047	11,064,752
Write-off of in-process research and development			10,422,130
Goodwill impairment			5,702,130
Equity in loss of investee			178,936
Total operating expenses	21,539,201	15,628,002	203,263,452
Loss from operations	(21,539,201)	(15,628,002)	(201,221,024)
Reduction of fair value of warrants			(12,239,688)
Interest income	60,268	73,560	4,892,476
Interest expense			(191,729)
Other income (expense), net	(1,352)	(5,047)	128,353
Loss before cumulative effect of change in accounting principle	(21,480,285)	(15,559,489)	(208,631,612)
Cumulative effect of change in accounting principle			(25,821)
Net loss	(21,480,285)	(15,559,489)	(208,657,433)
Preferred stock dividends			(621,240)
Deemed dividends on preferred stock			(10,506,683)
Net loss applicable to common stock	(21,480,285)	(15,559,489)	(219,785,356)
Loss per common share - basic and diluted	$ (0.28)	$ (0.33)
Weighted average shares outstanding - basic and diluted	76,585,752	47,641,043
Comprehensive Income/(Loss):
Net loss	(21,480,285)	(15,559,489)	(208,657,433)
Unrealized gains (losses) on marketable securities	(18,544)	104	(18,582)
Foreign currency translation adjustments			(2,156)
Comprehensive net loss	$ (21,498,829)	$ (15,559,385)	$ (208,678,171)